Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $6.8 million.

  • Harvard Bioscience's Cash & Equivalents rose 4920.11% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 4920.11%. This contributed to the annual value of $4.1 million for FY2024, which is 408.59% down from last year.
  • Per Harvard Bioscience's latest filing, its Cash & Equivalents stood at $6.8 million for Q3 2025, which was up 4920.11% from $7.4 million recorded in Q2 2025.
  • Harvard Bioscience's 5-year Cash & Equivalents high stood at $7.8 million for Q4 2021, and its period low was $3.8 million during Q1 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $5.1 million (2022), whereas its average is $5.2 million.
  • As far as peak fluctuations go, Harvard Bioscience's Cash & Equivalents skyrocketed by 13723.85% in 2021, and later tumbled by 4236.03% in 2022.
  • Quarter analysis of 5 years shows Harvard Bioscience's Cash & Equivalents stood at $7.8 million in 2021, then crashed by 42.36% to $4.5 million in 2022, then fell by 4.99% to $4.3 million in 2023, then dropped by 4.09% to $4.1 million in 2024, then skyrocketed by 65.94% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $7.4 million for Q2 2025, and $5.5 million during Q1 2025.